{"id":93760,"date":"2026-05-21T13:47:40","date_gmt":"2026-05-21T08:17:40","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=93760"},"modified":"2026-05-21T13:47:41","modified_gmt":"2026-05-21T08:17:41","slug":"divi-s-laboratories-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/","title":{"rendered":"Divi&#8217;s Laboratories Analyst Review May 2026"},"content":{"rendered":"<p><span style=\"font-size: revert; color: initial;\">This <\/span><strong style=\"font-size: revert; color: initial;\"><a href=\"https:\/\/univest.in\/user\/stocks\/divislab\/divi's-laboratories-ltd-share-price-today\">Divi&#8217;s Laboratories<\/a> analyst review<\/strong><span style=\"font-size: revert; color: initial;\"> for May 2026 covers the key data investors need for DIVISLAB at its current price of Rs 6,700.00. Divi&#8217;s Laboratories (NSE: DIVISLAB) is India&#8217;s largest pharmaceutical CDMO with a market capitalisation of approximately Rs 1,46,000 crore, specialising in Active Pharmaceutical Ingredients and custom synthesis. The analyst consensus target of Rs 6,000 implies meaningful upside, and this <\/span><strong style=\"font-size: revert; color: initial;\">Divi&#8217;s Laboratories analyst review<\/strong><span style=\"font-size: revert; color: initial;\"> examines technical levels, business performance, valuation, and key risks for DIVISLAB through FY27.<\/span><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Divis_Laboratories_Company_Snapshot_May_2026\" title=\"Divi&#8217;s Laboratories Company Snapshot May 2026\">Divi&#8217;s Laboratories Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Analyst_Insight_in_This_Divis_Laboratories_Analyst_Review\" title=\"Analyst Insight in This Divi&#8217;s Laboratories Analyst Review\">Analyst Insight in This Divi&#8217;s Laboratories Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Technical_Analysis_in_This_Divis_Laboratories_Analyst_Review\" title=\"Technical Analysis in This Divi&#8217;s Laboratories Analyst Review\">Technical Analysis in This Divi&#8217;s Laboratories Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#API_Manufacturing_Generics_Segment\" title=\"API Manufacturing (Generics Segment)\">API Manufacturing (Generics Segment)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Custom_Synthesis_for_Global_Innovator_Pharma\" title=\"Custom Synthesis for Global Innovator Pharma\">Custom Synthesis for Global Innovator Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Nutraceuticals_and_Carotenoids\" title=\"Nutraceuticals and Carotenoids\">Nutraceuticals and Carotenoids<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Valuation_in_This_Divis_Laboratories_Analyst_Review\" title=\"Valuation in This Divi&#8217;s Laboratories Analyst Review\">Valuation in This Divi&#8217;s Laboratories Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Trade_Outlook_for_Divis_Laboratories\" title=\"Trade Outlook for Divi&#8217;s Laboratories\">Trade Outlook for Divi&#8217;s Laboratories<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Key_Risks_for_Divis_Laboratories_in_FY27\" title=\"Key Risks for Divi&#8217;s Laboratories in FY27\">Key Risks for Divi&#8217;s Laboratories in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Conclusion_Divis_Laboratories_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Divi&#8217;s Laboratories Analyst Review Verdict for 2026\">Conclusion: Divi&#8217;s Laboratories Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Frequently_Asked_Questions_Divis_Laboratories_Analyst_Review_2026\" title=\"Frequently Asked Questions: Divi&#8217;s Laboratories Analyst Review 2026\">Frequently Asked Questions: Divi&#8217;s Laboratories Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#What_is_the_analyst_target_for_Divis_Laboratories_in_2026\" title=\"What is the analyst target for Divi&#8217;s Laboratories in 2026?\">What is the analyst target for Divi&#8217;s Laboratories in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Is_Divis_Laboratories_a_good_investment_at_Rs_670000\" title=\"Is Divi&#8217;s Laboratories a good investment at Rs 6,700.00?\">Is Divi&#8217;s Laboratories a good investment at Rs 6,700.00?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#What_is_Divis_Laboratoriess_52-week_high_and_low\" title=\"What is Divi&#8217;s Laboratories&#8217;s 52-week high and low?\">What is Divi&#8217;s Laboratories&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#What_are_the_key_risks_for_Divis_Laboratories\" title=\"What are the key risks for Divi&#8217;s Laboratories?\">What are the key risks for Divi&#8217;s Laboratories?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/divi-s-laboratories-analyst-review-2026\/#Where_can_I_track_live_data_for_Divis_Laboratories\" title=\"Where can I track live data for Divi&#8217;s Laboratories?\">Where can I track live data for Divi&#8217;s Laboratories?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Divis_Laboratories_Company_Snapshot_May_2026\"><\/span><strong>Divi&#8217;s Laboratories Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Divi&#8217;s supplies APIs and intermediates to over 100 global innovator pharmaceutical companies. Its China-plus-one supply chain position, zero-debt balance sheet, and 30 percent-plus EBITDA margins make it a premium-quality pharma holding. The table below summarises the key data referenced in this <strong>Divi&#8217;s Laboratories analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>DIVISLAB<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals &#8211; CDMO and APIs<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 6,700.00<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 7,071.50<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 5,636.50<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 1,46,000 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>60x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 6,000<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 7,200<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 3,800<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Divis_Laboratories_Analyst_Review\"><\/span><strong>Analyst Insight in This Divi&#8217;s Laboratories Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Associate Director <strong>Kunal Singla<\/strong> suggests watching Divi&#8217;s Laboratories closely in May 2026. At Rs 6,700.00, Kunal Singla flags Pharmaceuticals &#8211; CDMO and APIs sector dynamics as the primary driver for DIVISLAB&#8217;s near-term price action. He notes support in the Rs 5749 to Rs 6365 zone and flags any sustained close above Rs 7102 as a positive signal. Kunal Singla&#8217;s perspective on Divi&#8217;s Laboratories adds professional analysis to this <strong>Divi&#8217;s Laboratories analyst review<\/strong> and is not a buy recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Divis_Laboratories_Analyst_Review\"><\/span><strong>Technical Analysis in This Divi&#8217;s Laboratories Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 6,700.00, DIVISLAB is trading within its 52-week band of Rs 5,636.50 to Rs 7,071.50. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 5749 to Rs 6365 band while resistance is seen in the Rs 7102 to Rs 6350 zone. A sustained move above Rs 7102 could open the path toward the analyst consensus target of Rs 6,000 as identified in this <strong>Divi&#8217;s Laboratories analyst review<\/strong>.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 5749 to Rs 6365 &#8211; investors tracking this <strong>Divi&#8217;s Laboratories analyst review<\/strong> should watch for stabilisation or a bounce in this range as a potential accumulation signal for DIVISLAB.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 7102 to Rs 6350 &#8211; a sustained close above Rs 7102 would be a positive breakout signal worth flagging in this <strong>Divi&#8217;s Laboratories analyst review<\/strong>.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 6,000 represents the base-case upside scenario in this <strong>Divi&#8217;s Laboratories analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"API_Manufacturing_Generics_Segment\"><\/span><strong>API Manufacturing (Generics Segment)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Divi&#8217;s Laboratories, directly supporting the earnings trajectory toward the consensus target of Rs 6,000.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Custom_Synthesis_for_Global_Innovator_Pharma\"><\/span><strong>Custom Synthesis for Global Innovator Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Divi&#8217;s Laboratories&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Nutraceuticals_and_Carotenoids\"><\/span><strong>Nutraceuticals and Carotenoids<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Divi&#8217;s Laboratories and a key re-rating catalyst for the stock over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Divis_Laboratories_Analyst_Review\"><\/span><strong>Valuation in This Divi&#8217;s Laboratories Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 6,700.00, Divi&#8217;s Laboratories trades at a trailing P\/E of 60x. This <strong>Divi&#8217;s Laboratories analyst review<\/strong> presents three scenarios: a bull case of Rs 7,200 on strong earnings delivery, a base case of Rs 6,000 at analyst consensus, and a bear case of Rs 3,800 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this <strong>Divi&#8217;s Laboratories analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 7,200<\/td>\n<td>Strong earnings delivery and sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 6,000<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 3,800<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Divis_Laboratories\"><\/span><strong>Trade Outlook for Divi&#8217;s Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Divi&#8217;s Laboratories analyst review<\/strong>, investors might watch DIVISLAB near the support zone of Rs 5749 to Rs 6365 for potential opportunities. A flag above Rs 7102 could suggest improving momentum toward Rs 6,000. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Divis_Laboratories_in_FY27\"><\/span><strong>Key Risks for Divi&#8217;s Laboratories in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Divi&#8217;s Laboratories analyst review<\/strong> must assess downside risks. Key risks for Divi&#8217;s Laboratories include a macro slowdown affecting Pharmaceuticals &#8211; CDMO and APIs sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in DIVISLAB.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Divis_Laboratories_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Divi&#8217;s Laboratories Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Divi&#8217;s Laboratories analyst review<\/strong> concludes that at Rs 6,700.00, DIVISLAB offers a defined risk-reward with a consensus target of Rs 6,000. The 52-week range of Rs 5,636.50 to Rs 7,071.50 provides context on the current entry point. Use this <strong>Divi&#8217;s Laboratories analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on DIVISLAB.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Divis_Laboratories_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Divi&#8217;s Laboratories Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Divis_Laboratories_in_2026\"><\/span><strong>What is the analyst target for Divi&#8217;s Laboratories in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 6,000, with a bull case of Rs 7,200 and a bear case of Rs 3,800. This <strong>Divi&#8217;s Laboratories analyst review<\/strong> recommends monitoring Q1 FY27 earnings for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Divis_Laboratories_a_good_investment_at_Rs_670000\"><\/span><strong>Is Divi&#8217;s Laboratories a good investment at Rs 6,700.00?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 6,700.00 with a P\/E of 60x and a consensus target of Rs 6,000, this <strong>Divi&#8217;s Laboratories analyst review<\/strong> is constructive for medium to long-term investors in the Pharmaceuticals &#8211; CDMO and APIs sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Divis_Laboratoriess_52-week_high_and_low\"><\/span><strong>What is Divi&#8217;s Laboratories&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 7,071.50 and the 52-week low is Rs 5,636.50. At Rs 6,700.00, DIVISLAB is positioned within this range as noted in this <strong>Divi&#8217;s Laboratories analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Divis_Laboratories\"><\/span><strong>What are the key risks for Divi&#8217;s Laboratories?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals &#8211; CDMO and APIs sector as assessed in this <strong>Divi&#8217;s Laboratories analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_live_data_for_Divis_Laboratories\"><\/span><strong>Where can I track live data for Divi&#8217;s Laboratories?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Divi&#8217;s Laboratories&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this <strong>Divi&#8217;s Laboratories analyst review<\/strong>.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Divi&#8217;s Laboratories analyst review 2026: CMP Rs 6,700.00, MCap Rs 1,46,000 Cr, PE 60x. Pharmaceuticals &#8211; CDMO and APIs sector outlook and technical levels. May<\/p>\n","protected":false},"author":35,"featured_media":94064,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-93760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779351476:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["75"],"rank_math_title":["Divi's Laboratories Analyst Review 2026"],"rank_math_description":["Divi's Laboratories analyst review 2026: CMP Rs 6,700.00, MCap Rs 1,46,000 Cr, PE 60x. Pharmaceuticals - CDMO and APIs sector outlook and technical levels.\u00a0"],"rank_math_focus_keyword":["Divi's Laboratories analyst review"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["94064"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12765"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/21134618\/Divis-Laboratories.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=93760"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93760\/revisions"}],"predecessor-version":[{"id":94069,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93760\/revisions\/94069"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/94064"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=93760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=93760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=93760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}